Category: Events

5th Annual Science Meeting

October 10-11th 2018
British Medical Association House, Central London
Come and join the bioprocessing community at our 5th Annual Science meeting.
A wait list is now in place
https://www.surveymonkey.co.uk/r/BioProNET2018wait

“The 2017 meeting was one of the most interesting and educational that I have attended in a while!”

Wednesday October 10th
9.30 Registration (if you arrive before registration you are welcome to use the BMA cafe)
10.15-10.30 Welcome, achievements and what next for BioProNET
Designing more efficient cell-expression systems chaired by Mark Smales
10.30-10.55 Kerstin Otte
 University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics 
11.20-11.30 Andrew Peden University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells 
11.30-11.55 Nathan Lewis University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing
11.55-12.10 Simon Saxby Leaf Expression Systems Plant produced biologics – process economics

12.10-13.15 Lunch

Building expression systems into optimised process chair TBC
13.15-13.40 Gary Finka GlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.40-14.05 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.05-14.15 Gary Montague Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.15-14.25 James Winterburn University of Manchester From bench to business with UKRI funding
14.25–14.50 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products

14.50-15.30 refreshment break and networking

The clinic and beyond chaired by Laura Palomares
15.30-15.55 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
15.55-16.20 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
16.20-16.30 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.30-16.40 Pavlos Kotidis Imperial College London A mathematical model to describe CHO cell growth and monoclonal antibody glycosylation

Hotel check-in
18.00 Poster session
20.00 Conference dinner

Thursday October 11th
Upstream meets downstream – rapid process development chair TBC
9.00-9.25 Paul Dalby University College London New analytical methods for chromatography; further downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Martyn Hulley MedImmune Nucleic acid purification for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Davide Vito University of Kent Translation engineering through the non-coding genome in CHO cells
10.35-11.00 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins

11.00-11.40 refreshment break and networking

Molecular characterisation of process quality chaired by Alan Dickson
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Rosa Morra University of Manchester Classical and non-classical secretion pathways in E. coli for periplasmic and extracellular recombinant protein production
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry

13.15-14.00 Poster prizes and lunch
14.00-16.00 Optional collaboration-building session

Timings may change due to logistical needs

waiting list: https://www.surveymonkey.co.uk/r/BioProNET2018wait

Screen Shot 2017-10-25 at 16.12.18

Manufacturing ATMPs – moving from approvable to commercial success

Registration is now open for this conference organised by the Future Targeted Healthcare Manufacturing Hub, in partnership with the Knowledge Transfer Network (KTN), to be held on 18th September at Woburn House Conference Centre in London. The meeting will focus on the current UK innovation landscape for advanced therapies, in support of enabling gene and cell therapy products to go from approvable to commercially successful. We will also hear about translational research projects in support of manufacturing readiness, in addition to a future looking session regarding key challenges from clinical, regulatory and skills perspectives. The Hub and KTN partner to deliver this meeting enabling industry and academia engagement and collaboration, and showcasing of the relevant translational research being undertaken by the Hub in collaboration with industry.

We are expecting about 100 delegates on the day from the wider sector. The event is free to attend for the community. The agenda will be published soon.

Call for Posters
There will be a chance for researchers from both academia and industry to share and present relevant posters. Please note your interest on registration and use the free text box to indicate the title (or short descriptor).

Further information
Please note, places for this event are limited and if the meeting is oversubscribed, places will be prioritised for those who are technical practitioners in the sector. We may need to limit number of representatives from any one organisation.
For any queries please contact Marcel Kuiper

BioProNET-funded collaboration-building workshops

Using big data and computational methods in bioprocessing
June 11th, University of Kent, Canterbury
9.30am (registration), 10am–5.00pm

The continuing advances in computational methods and the greater use of high throughput omics approaches has increased the potential for greater application of these methods in bioprocessing. This workshop will focus on a number of main areas including: 1) antibody design, 2) use of genetic variation when analysing CHO cells for biologics production 3) protein modelling to investigate properties such as aggregation and binding of host cell impurities to biologics.
Confirmed speakers include Charlotte Deane, University of Oxford, Mark Wass, University of Kent and Nicole Borth, Universität für Bodenkultur, Vienna, Austria.
For more details contact Mark Wass
To register: https://www.surveymonkey.co.uk/r/BioProNET_BigData
Travel: If you are coming by train via London, then Canterbury is less than one hour from London St Pancras. More travel details here https://www.kent.ac.uk/locations/canterbury/directions.html

The promise of genome editing: changing bioprocessing, manufacture and much more
18th June, Bradfield Centre, Cambridge Science Park, 11am–4pm
Confirmed speakers include Nicola McCarthy, Horizon Discovery; Mark Fife, Pirbright Institute; Lorenz Mayr, GE Healthcare and Claus Kristensen, University of Copenhagen.
Evolution is so ‘yesterday’ as we enter the revolution offered by genome editing. You may find this opinion provocative but if the cellular systems we have are not good enough for the functions needed, why should we not just build new ones by changing the genetic makeup of the cell, So far, so good… the promise remains but what is the reality of this hope? In this workshop we are bringing together expert opinion leaders from academia and industry to examine the likelihood of the expectations being translated to outcomes. Via short expert presentations and focused group discussions, the participants will examine how the potential of genome editing to change the manufacture of bio-based products may be enhanced and the practical consequences of such interventions from a commercial perspective.

Registration link and more information: http://app1.horizondiscovery.com/biopronet-2018-event-application

Bioprocess Intensification
July 4th, University College London 9.30am–5.30pm
The continued growth of the biopharmaceutical industry is being challenged by a greater number and variety of products than in the past. The industry is also increasingly concerned with the affordability of these products. These key factors means process intensification has become a critical objective. The goal is higher productivity processes to enable small process trains, resulting in cost-effective, lean, and agile manufacturing facilities. The symposium assembles 8 leaders from the biopharmaceutical industry and academia (Line Lundsberg-Nielsen (NNE), Hani El-Sabbahy (3M/UCL), Ajoy Velayudhan (UCL) Peter Levison (Pall), Will Lewis (GSK), Jonathan Souquet (Merck KGaA), John Welsh (Pall) Suzy Farid (UCL)) who will present their latest findings and opinions on the subject. By bringing together scientists and engineers from academia and industry who are actively engaged in bioprocess intensification the event will provide forum for lively debate.

Registration here: https://www.surveymonkey.co.uk/r/BioProNET_BioprocessIntensification
The programme is available here
Directions: https://www.ucl.ac.uk/maps/jz-young-lt

 

 

Latin-American Symposium on Animal Cell Technology

The 8th Latin-American Symposium on Animal Cell Technology (SLATCC) is a conference focused on Pharmaceutical Biotechnology that will take place in Rio de Janeiro, Brazil, from October 21st to 24th, 2018.

In its 8th edition, the meeting will have plenary talks, oral presentations and poster presentations, as well as an exhibition of vendors and equipment suppliers. The oral language of activities will be Spanish, Portuguese and English, without simultaneous translation. Written materials, including posters and slides, will be prepared in English.

The deadline for submission of abstracts is July 16th, 2018. Oral and poster sessions will focus on the following topics:
– Biopharmaceutical trends
– Genome editing and cell line development
– Upstream process development
– Downstream process development
– Continuous and integrated processes
– Product development and product quality
– Biosimilars
– Viral and recombinant vaccines
– Cell and nucleic acid therapies

Coference website http://slatcc2018.peq.coppe.ufrj.br/index.html

BioProNET 4th annual science meeting

Photo taken by Linas Tamosaitis DSC06933

Some feedback from our 4th Annual Science meeting, held in October 2017:
“The meeting was one of the most interesting and educational that I have attended in a while!”

“Excellent chances to meet and build links with the community”

“I really appreciated the diversity of the speaker, e.g. male versus female, experienced verses ECR, academic versus industry”

Our 4th Annual Science Meeting featured the following line-up:

Designing more efficient cell-expression systems (chaired by Paula Alves)
Helene Faustrup Kildegaard – Technical University of Denmark: Improving CHO cell factories with CRISPR-mediated genome engineering
Eva Pekle – University of Kent: Single cell characterisation of CHO cells
Imre Berger – University of Bristol: Baculovirus expression: old dog, new tricks
David Humphreys UCB: Protein expression demands and demanding protein expressions: protein sciences the biopharma way
Stefanie Frank – University College London: Engineering spatial segregation within bacterial hosts for bio-therapeutic protein production
Karen CoopmanLoughborough University: Taking a holistic approach to mesenchymal stem cell culture process design
Robyn Emmins – GlaxoSmithKline: Embedding the Berkeley Lights Beacon: a bright future for cell line development